GHK (Glycine-Histidine-Lysine Tripeptide) vs KPV
A neutral, side-by-side comparison of two healing & recovery peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
GHK (Glycine-Histidine-Lysine Tripeptide)
The free tripeptide component of GHK-Cu before copper complexation. GHK naturally occurs in human plasma, saliva, and urine and promotes wound healing, collagen synthesis, and anti-inflammatory activity. While it readily chelates copper to form GHK-Cu in vivo, research distinguishes the independent effects of free GHK from the copper-complexed form on gene expression and tissue remodeling.
Full profileKPV
KPV is a C-terminal tripeptide fragment (Lys-Pro-Val) of alpha-melanocyte stimulating hormone (α-MSH). Despite its small size — just three amino acids — it retains the anti-inflammatory core activity of its parent molecule without the melanogenic effects. It is one of the most researched peptides for gut inflammation, IBD, and intestinal permeability, with the ability to act locally in the gut when administered orally.
Full profile| GHK (Glycine-Histidine-Lysine Tripeptide) | KPV | |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| Also known as | GHK tripeptide, Gly-His-Lys, copper chelating tripeptide, GHK free tripeptide | Lys-Pro-Val, Alpha-MSH C-terminal tripeptide |
| Evidence | Research-stage | Research-stage |
| Dosing range | 0.5mg–2mg mg, Daily or every other day (topical or SC) | 250mcg–1000mcg mcg, Once or twice daily |
| Administration | Subcutaneous injection, Topical (cream/serum) | Subcutaneous injection, Oral (encapsulated — for gut-specific delivery), Intranasal |
| Key side effects | Minimal reported side effects, Mild injection site irritation, Rare topical sensitization, No significant systemic effects at research doses | Generally well-tolerated, Mild injection site irritation, Transient headache (uncommon), No melanogenic effects (does not cause tanning unlike full α-MSH) |
| Cited sources | 2 references | 3 references |
Key differences
- Administration: GHK (Glycine-Histidine-Lysine Tripeptide) — Subcutaneous injection, Topical (cream/serum); KPV — Subcutaneous injection, Oral (encapsulated — for gut-specific delivery), Intranasal.
- Dosing units differ: GHK (Glycine-Histidine-Lysine Tripeptide) is dosed in mg, KPV in mcg — they operate at different scales.
- Frequency: GHK (Glycine-Histidine-Lysine Tripeptide) is typically Daily or every other day (topical or SC); KPV is Once or twice daily.
- Research depth: this profile cites 2 sources for GHK (Glycine-Histidine-Lysine Tripeptide) vs 3 for KPV.
How each works
GHK (Glycine-Histidine-Lysine Tripeptide)
Free GHK directly upregulates collagen, elastin, and laminin synthesis in fibroblasts through TGF-β pathway activation and metalloproteinase modulation. Loren Pickart's decades of research identified GHK as a potent tissue remodeling signal whose plasma concentrations decline with age. At physiologic concentrations, GHK resets approximately 31% of dysregulated gene expression associated with aging back toward a younger phenotype.
KPV
KPV exerts anti-inflammatory effects through melanocortin receptor-independent mechanisms as well as via MC1R and MC3R activation. It downregulates NF-κB, inhibits pro-inflammatory cytokines (TNF-α, IL-1β, IL-8), and reduces neutrophil infiltration in colonic tissue. Uniquely for a peptide, KPV is acid-stable enough to survive gastric transit and reach the intestinal mucosa intact, making oral delivery viable for gut-targeted applications — a significant advantage over most injectable-only peptides.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.